The major players in the immunofluorescence assay market are Thermo Fisher Scientific, Inc., Abcam plc, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Werfen Company, Merck KGaA, Agilent Technologies, Becton Dickinson and Company, Maxvision Biosciences Inc.
NEW YORK, Sep 9, 2022 (GLOBE NEWSWIRE) – Reportlinker.com announces release of “Immunofluorescence assay, 2022 Global Market Report” – https://www.reportlinker.com/p06318511/?utm_source=GNW
J. Mitra & Co., Zyagen. soldier. Ltd. and AESKU GROUP GmbH and Vector Laboratories, Inc. and EpiGentek Group and Elabscience, Inc.
The global immunofluorescence assay market is expected to grow from $2.71 billion in 2021 to $2.90 billion in 2022 at a compound annual growth rate (CAGR) of 6.93%. The immunofluorescence assay market is expected to grow to $3.68 billion in 2026 with a compound annual growth rate (CAGR) of 6.14%.
The immunofluorescence assay market consists of sales of immunofluorescence assay and related products by entities (organizations, sole traders, partnerships) referring to equipment and consumables that operate on a technology, allowing visualization of a specific protein and antigen in infected cells based on the ability to interact with Specific antibodies by binding a specific antibody chemically conjugated to a fluorescent dye. It is a technique used in the laboratory to diagnose diseases of the skin, kidneys, heart, cilia, and other organ systems.
The main types of immunofluorescence assay include direct immunofluorescence and indirect immunofluorescence. Direct immunofluorescence refers to a laboratory technique for diagnosing diseases of the skin, kidneys and other organ system diseases.
Direct immunofluorescence uses a single antibody directly conjugated to the fluorescence dye. Various products for immunofluorescence assay include reagents, instruments, antibodies, kits, consumables and accessories.
They are used to diagnose various diseases including cancer, infectious diseases, autoimmune diseases, and others. They are used by academic and research institutions, pharmaceutical and biotechnology companies, hospitals, diagnostic centers and contract research organizations.
North America was the largest region in the immunofluorescence assay market in 2021, and it is also expected to be the fastest growing region in the forecast period. The regions covered in the Immunofluorescence Assay market report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East & Africa.
Immunofluorescence Assay Market Research Report is one of a series of new reports providing Immunofluorescence Assay market statistics, including global Immunofluorescence Assay industry market size, regional shares, competitors with Immunofluorescence Assay market share, and Detailed Immunofluorescence Assay market segments , market trends, opportunities, and any other data you may need to thrive in the Immunofluorescence Assay industry. This Immunofluorescence Screening Market Research Report offers a complete perspective on everything you need, with an in-depth analysis of current and future scenarios of the industry.
The increasing prevalence of chronic diseases is significantly driving the growth of the immunofluorescence assay market, where change of lifestyle, dietary habits and improper weight management contribute to the rapid growth in chronic conditions and few long-term chronic infections lead to cancer risks.
The increasing prevalence of chronic diseases is expected to increase the demand for immunofluorescence assays as they are widely used in diagnostic and drug development activities. For example, according to the study published by the Centers for Disease Control and Prevention, nearly 6 out of 10 adults in the United States are affected by chronic diseases, and they account for $3.8 trillion in annual health care costs. Therefore, the increasing prevalence of chronic diseases is expected to increase the demand for immunofluorescence assay during the prediction period.
Technological advancement is a major trend gaining popularity in the immunofluorescence assay market. Companies involved in the immunofluorescence assay are focused on developing technologically innovative products to meet the specific technical requirements for diagnosing new viruses such as COVID-19 and to strengthen their market position.
For example, in March 2022, LumiraDx, a UK developer of point-of-care diagnostics, received emergency approval for the LumiraDx SARS-CoV-2 Ag test, a microfluoric immunofluorescence assay, designed to detect specific protein antigen from a nasal swab. samples.
In July 2019, Germany-based AESKU Group, a developer of rapid test systems for blood diagnostics and immunoassays, acquired MBL Bion for an undisclosed amount. Through this acquisition, AESKU is focusing on reducing order processing and delivery times.
In addition, the high-quality MBLBion HEp-2 cells and comprehensive infectious disease test strips add tremendous value to the new “HTC” HELIOS Temperature and Humidity Controller from AESKU. MBL Bion is a US-based manufacturer of high quality IFA products for medical laboratories.
The countries covered in the immunofluorescence assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Read the full report: https://www.reportlinker.com/p06318511/?utm_source=GNW
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you have all the market research you need – instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001